- Trial phase
- Approved
- Time to market
- Already on the market since 2003; the 2026-2027 seasonal formulation is currently available.
- Why 3/10
- No hard, dated binary catalyst is scheduled in the next ~12 months. FluMist is an already-approved, marketed seasonal product with no pending PDUFA, pivotal readout, or AdComm. The annual strain update and seasonal availability are routine commercial events, not binary catalysts. ImpactScore is 3 because this is an approved product with no pending regulatory decision and it represents a very small fraction of AstraZeneca's diversified ~$62B revenue base.
FluMist is an already-approved, seasonal product with no binary regulatory catalysts on the horizon. The key commercial metric to watch is whether FluMist Home (at-home delivery) drives meaningful market share gains in the 2026-2027 flu season, but given FluMist's small contribution to AstraZeneca's ~$62B revenue base, even a strong season would barely move the stock. The next meaningful event would be the 2027-2028 strain composition update, which is routine and non-binary.
Price Chart
Executive Summary
FluMist is AstraZeneca's live attenuated influenza vaccine delivered as a nasal spray, the only needle-free flu vaccine option in the US. Originally approved by the FDA in 2003 and developed by MedImmune (acquired by AstraZeneca in 2007), it is indicated for ages 2 through 49. A landmark FDA approval in September 2024 allowed self- or caregiver-administration, and AstraZeneca launched FluMist Home (at-home mail delivery) for the 2025-2026 season. The 2026-2027 season formulation is now available. However, FluMist is a very small part of AstraZeneca's business: vaccines and immune therapies combined generated only ~$846M in 2025 against total company revenue of ~$58.7B. With no pending regulatory binary catalysts, FluMist is a steady but non-material contributor to AstraZeneca's diversified portfolio.
How It Works
FluMist is a live attenuated influenza vaccine (LAIV) delivered as a nasal spray. It contains weakened live influenza viruses that are designed to replicate in the cooler temperature of the nose, stimulating the body's immune system to produce antibodies against the flu without causing illness. Because it is sprayed into the nose rather than injected with a needle, it mimics the natural route of flu infection and triggers both systemic and local (nasal) immune responses. It is reformulated each year to match the influenza strains expected to circulate in the upcoming season.
Trial Status
FluMist is an FDA-approved, commercially marketed product. It was originally approved in June 2003, with a key label expansion in September 2024 allowing self- or caregiver-administration. The 2026-2027 seasonal formulation is currently available in the US through healthcare settings and via FluMist Home at-home delivery.
The Two-Sided Case
Upcoming Catalysts
- No binary regulatory catalysts are scheduled. The product is already approved and commercialized. Routine seasonal updates (strain composition for 2027-2028) occur annually but are not stock-moving events for a company of AstraZeneca's size.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ASTRAZENECA PLC 6-K AZN ·Originating report